CSTL Castle Biosciences, Inc.
Price Chart
Executive Summary
Castle Biosciences announced new prospective, multicenter study data showing that its DecisionDx-Melanoma test, via the i31-SLNB algorithm, accurately identifies melanoma patients with less than 5% predicted risk of sentinel lymph node (SLN) positivity—aligning with NCCN guidelines to forgo SLNB. Patients with low-risk results had only 2.6% actual SLN positivity and 97.8% three-year recurrence-free survival, supporting clinical utility and potential to reduce unnecessary surgeries.
Actionable Insight
Traders should monitor test adoption trends and potential inclusion in broader clinical guidelines; this level of prospective validation may drive increased payer coverage and physician uptake, supporting revenue growth.
Key Facts
- New data from a prospective, multicenter study of 912 patients shows DecisionDx-Melanoma’s i31-SLNB test accurately stratifies SLN positivity risk.
- Patients with <5% predicted risk had 2.6% actual SLN positivity; in T1b–T2a subgroup, it was just 1.4%.
- High-risk patients (>10% predicted) had 21.4% actual SLN positivity (13.2x higher than low-risk).
- Low-risk patients showed 97.8% three-year recurrence-free survival.
- Study supports test’s ability to reduce unnecessary SLNBs while maintaining strong outcomes.
- Data presented at SSO 2026 and accepted for publication in Future Oncology.
Financial Impact
Potential for increased test adoption and revenue growth as clinical validation strengthens; no direct financial figures provided.
Risk Factors
- Forward-looking statements: actual adoption may not match expectations.
- Reimbursement challenges or payer resistance could limit commercial impact.
- Future studies could contradict current findings.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251673 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $20.89 awaiting T+1 | awaiting T+1 | — | $20.70 (+0.91%) |
|
Jun 1, 2026
13d ago
|
144
| $19.71 $20.39 | ▲ +3.45% | ▲ +4.17% | $20.70 (+5.02%) |
|
May 7, 2026
5w ago
|
144
| $19.83 $19.04 | ▼ −3.98% | ▼ −4.22% | $20.70 (+4.39%) |
|
Apr 8, 2026
9w ago
|
DEFA14A
| $25.19 $23.43 | ▼ −6.99% | ▼ −7.56% | $20.70 (−17.82%) |
|
Mar 13, 2026
13w ago
|
Press Release
| $25.56 $25.83 | ▲ +1.06% | ▲ +0.03% | $20.70 (−19.01%) |
|
Mar 12, 2026
13w ago
|
Insider Cluster
| $25.32 $25.56 | ▼ −0.95% | ▼ −1.55% | $20.70 (+18.25%) |
|
Mar 12, 2026
13w ago
|
Insider Cluster
| $25.32 $25.56 | ▼ −0.95% | ▼ −1.55% | $20.70 (+18.25%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $27.02 $26.60 | ▼ −1.55% | ▼ −1.37% | $20.70 (−23.39%) |
|
Mar 5, 2026
14w ago
|
Insider Cluster
| $27.91 $27.12 | ▲ +2.83% | ▲ +1.52% | $20.70 (+25.83%) |
|
Mar 5, 2026
14w ago
|
Insider Cluster
| $27.91 $27.12 | ▲ +2.83% | ▲ +1.52% | $20.70 (+25.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access